Other
Intracytoplasmic Sperm Injection
0
Pipeline Programs↗
1
Active Trials↗
2
Companies Involved↗
Intracytoplasmic Sperm Injection is an early-stage landscape with 0 programs across 2 companies. The most active players are Ferring, Merck & Co..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
20
clinical trials
Completed14 · 70%
Unknown status3 · 15%
Active, not recruiting1 · 5%
Terminated1 · 5%
Withdrawn1 · 5%
Clinical Trials
Trial Activity
20 trials
Buscopan in Patients Undergoing IVF/Intracytoplasmic Sperm Injection Treatment
Active, not recruiting·—·N/A·NCT04751084·675 enrolled
Use of Antioxidant in Endometriotic Women to Improve Intracytoplasmic Sperm Injection (ICSI)
Completed·—·Phase 2·NCT02058212·50 enrolled
Metformin in Intracytoplasmic Sperm Injection Cycles
Completed·—·Phase 2·NCT03088631·320 enrolled
Effect of GH Administration in Poor Responders Undergoing Intracytoplasmic Sperm Injection (ICSI)
Completed·—·Phase 4·NCT05281341·160 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)